Sana Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Sana Biotechnology, Inc. (SANA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 6.32 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-10
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 881.00K shares, a 8.36% increase year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 5.43M shares, a 15.99% increase year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 501.00K shares, a 70.99% increase year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 9.00K shares, a 98.70% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 6.01M shares, a 23.28% decline from fiscal 2024.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 7.83M shares, a 7.15% decline from fiscal 2023.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 8.43M shares, a 29.42% decline from fiscal 2022.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 11.95M shares, a 186.89% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 881.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 6.32M shares 10-Q · filed 2026-08-10 | 6.82M shares derived: sum of 3 quarters · filed 2026-08-10 | 6.83M shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 5.43M shares 10-Q · filed 2026-05-11 | 5.93M shares derived: sum of 2 quarters · filed 2026-05-11 | 5.94M shares derived: sum of 3 quarters · filed 2026-05-11 | 6.76M shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 501.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 510.00K shares derived: sum of 2 quarters · filed 2026-03-03 | 1.32M shares derived: sum of 3 quarters · filed 2026-03-03 | 6.01M shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 9.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 822.00K shares derived: sum of 2 quarters · filed 2025-11-06 | 5.51M shares 10-Q · filed 2025-11-06 | 5.80M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 813.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 5.50M shares 10-Q · filed 2025-08-11 | 5.79M shares derived: sum of 3 quarters · filed 2025-08-11 | 6.48M shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 4.68M shares 10-Q · filed 2025-05-08 | 4.98M shares derived: sum of 2 quarters · filed 2025-05-08 | 5.67M shares derived: sum of 3 quarters · filed 2025-05-08 | 6.96M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 293.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | 983.00K shares derived: sum of 2 quarters · filed 2025-03-17 | 2.28M shares derived: sum of 3 quarters · filed 2025-03-17 | 7.83M shares 10-K · filed 2025-03-17 |
| 2024-09-30 | 690.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | 1.99M shares derived: sum of 2 quarters · filed 2024-11-08 | 7.54M shares 10-Q · filed 2024-11-08 | 7.81M shares derived: sum of 4 quarters · filed 2024-11-08 |
| 2024-06-30 | 1.30M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 6.85M shares 10-Q · filed 2024-08-08 | 7.12M shares derived: sum of 3 quarters · filed 2024-08-08 | 7.32M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 5.55M shares 10-Q · filed 2024-05-08 | 5.82M shares derived: sum of 2 quarters · filed 2024-05-08 | 6.03M shares derived: sum of 3 quarters · filed 2024-05-08 | 7.92M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 273.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 475.00K shares derived: sum of 2 quarters · filed 2024-02-29 | 2.37M shares derived: sum of 3 quarters · filed 2024-02-29 | 8.43M shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 202.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 2.09M shares derived: sum of 2 quarters · filed 2023-11-08 | 8.16M shares 10-Q · filed 2023-11-08 | 8.73M shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 1.89M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 7.96M shares 10-Q · filed 2023-08-03 | 8.53M shares derived: sum of 3 quarters · filed 2023-08-03 | 10.05M shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 6.07M shares 10-Q · filed 2023-05-08 | 6.64M shares derived: sum of 2 quarters · filed 2023-05-08 | 8.16M shares derived: sum of 3 quarters · filed 2023-05-08 | 9.97M shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 574.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 2.10M shares derived: sum of 2 quarters · filed 2023-03-16 | 3.90M shares derived: sum of 3 quarters · filed 2023-03-16 | 11.95M shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 1.52M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | 3.33M shares derived: sum of 2 quarters · filed 2022-11-02 | 11.38M shares 10-Q · filed 2022-11-02 | 12.14M shares derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | 1.81M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 9.85M shares 10-Q · filed 2022-08-04 | 10.62M shares derived: sum of 3 quarters · filed 2022-08-04 | 12.46M shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 8.04M shares 10-Q · filed 2022-05-10 | 8.81M shares derived: sum of 2 quarters · filed 2022-05-10 | 10.65M shares derived: sum of 3 quarters · filed 2022-05-10 | 11.68M shares derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 767.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | 2.61M shares derived: sum of 2 quarters · filed 2022-03-16 | 3.64M shares derived: sum of 3 quarters · filed 2022-03-16 | 4.17M shares 10-K · filed 2022-03-16 |
| 2021-09-30 | 1.84M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 2.87M shares derived: sum of 2 quarters · filed 2021-11-08 | 3.40M shares 10-Q · filed 2021-11-08 | |
| 2021-06-30 | 1.03M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | 1.56M shares 10-Q · filed 2021-08-04 | ||
| 2021-03-31 | 526.00K shares 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |